Anticoagulation For Pulmonary Hypertension in Sickle Cell Disease
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Sickle cell disease (SCD) is often referred to as a hypercoagulable state. However, the contribution of coagulation activation to the pathogenesis of SCD remains uncertain. Pulmonary hypertension (PHT) is a common complication associated with significant morbidity and mortality. Autopsy studies of SCD patients with PHT show evidence of in situ thrombosis involving pulmonary vessels, similar to findings in non-sickle cell patients with PHT. Anticoagulation has been reported to be of benefit in non-sickle cell patients with PHT. With the evidence of increased coagulation activation in SCD, PHT represents a clinical endpoint that may be used to evaluate the contribution of coagulation activation to the pathophysiology of SCD. The investigators hypothesize that increased thrombin generation, as well as platelet activation are central to the pathophysiology of SCD and contribute to the occurrence of several SCD-related complications, including PHT. As a consequence, treatment modalities that down-regulate thrombin generation would be expected to delay the progression of PHT and result in improved survival in patients with SCD.
| Condition | Intervention | Phase |
|---|---|---|
|
Pulmonary Hypertension |
Drug: Warfarin |
Phase 2 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Parallel Assignment Masking: Double Blind (Subject, Caregiver, Investigator) Primary Purpose: Treatment |
| Official Title: | An Exploratory Study of Anticoagulation For Pulmonary Hypertension in Sickle Cell Disease |
- The effect of anticoagulation on pulmonary artery systolic pressure obtained by Doppler echocardiography [ Time Frame: Measurements will be obtained at Screening, Prior to Run-in, and at Months 3, 6, 9, and 12 ] [ Designated as safety issue: No ]
- 6-minute walk test [ Time Frame: Measurements will be obtained at Screening, Prior to Run-in, and at Months 3, 6, 9, and 12 ] [ Designated as safety issue: No ]
- Thrombin generation [ Time Frame: Measurements will be obtained at Screening, Prior to Run-in, and at Months 3, 6, 9, and 1 ] [ Designated as safety issue: No ]
- Platelet activation [ Time Frame: Measurements will be obtained at Screening, Prior to Run-in, and at Months 3, 6, 9, and 1 ] [ Designated as safety issue: No ]
- Endothelial Activation [ Time Frame: Measurements will be obtained at Screening, Prior to Run-in, and at Months 3, 6, 9, and 1 ] [ Designated as safety issue: No ]
- All-cause mortality [ Time Frame: Measurements will be obtained at Screening, Prior to Run-in, and at Months 3, 6, 9, and 1 ] [ Designated as safety issue: No ]
- Safety [ Time Frame: Measurements will be obtained at Screening, Prior to Run-in, and at Months 3, 6, 9, and 1 ] [ Designated as safety issue: No ]
| Estimated Enrollment: | 20 |
| Study Start Date: | December 2009 |
| Estimated Study Completion Date: | December 2013 |
| Estimated Primary Completion Date: | December 2013 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Active Comparator: Warfarin
Patients on the active treatment arm will be anticoagulated using the vitamin K antagonist, warfarin
|
Drug: Warfarin
Patients on the active treatment arm will receive warfarin to achieve a target INR of between 2 and 3
Other Name: Coumadin
|
| Placebo Comparator: Placebo |
Drug: Warfarin
Patients on the active treatment arm will receive warfarin to achieve a target INR of between 2 and 3
Other Name: Coumadin
|
Detailed Description:
As a result of the presence of large vessel thrombotic complications, as well as the biochemical evidence of ongoing coagulation activation, sickle cell disease (SCD) is often referred to as a hypercoagulable state. However, the contribution of coagulation activation to the pathogenesis of SCD remains uncertain. While the majority of clinical studies using anticoagulants have shown no convincing benefit in the prevention or treatment of acute pain episodes, most of these studies were small and poorly controlled. Furthermore, because the acute pain episode appears to result from the occlusion of postcapillary venules by the interaction of red blood cells and other cellular elements with the vascular endothelium and subendothelial matrix proteins, it may not be the ideal clinical endpoint for assessing the effect of anticoagulation in SCD patients. Pulmonary hypertension (PHT), a common complication associated with significant morbidity and mortality, and with histopathologic findings of in situ thrombosis involving pulmonary vessels, represents a clinical endpoint that is likely due, at least in part, to increased thrombin generation, and may therefore be used to evaluate the contribution of coagulation activation to the pathophysiology of SCD. Twenty patients with sickle cell anemia (HbSS) or sickle beta zero thalassemia (Sickle beta zero thalassemia) and mild PHT who meet the eligibility requirements will be enrolled, 10 patients to receive anticoagulation with warfarin and 10 to receive placebo rfor 12 months of treatment.
Eligibility| Ages Eligible for Study: | 16 Years to 65 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- At least 16 years of age
- Have a confirmed diagnosis of sickle cell anemia (HbSS) or sickle cell beta zero thalassemia
- Have evidence of persistent elevation of PASP on Doppler echocardiography (TR jet velocity of 2.5 to 2.9 m/s [or estimated PASP above the upper limit of reference adjusted ranges and up to 45 mm Hg]), but no evidence of moderate or severe diastolic dysfunction on tissue Doppler echocardiography. Mild PHT must be confirmed on repeat evaluation, at least 3 months later
- Have a serum creatinine =/< 1.5 mg/dl
- Have serum transaminase values (ALT) < 2 times upper limits of normal
- Have serum albumin =/> 3.2 g/dl
- Have a platelet count =/< 150,000 cu/mm
- Have normal baseline coagulation profile (PT/INR, PTT)
- Patients on treatment with hydroxyurea should be on a stable dose for at least 6 months. Doses of hydroxyurea may only be adjusted during the course of the study for safety reasons.
- Be able to understand the requirements of the study and be willing to give informed consent.
- Women of childbearing age must be practicing (and will continue to practice for the course of the study) an adequate method of contraception.
Exclusion Criteria:
- Have a baseline hemoglobin < 6.0 gm/dl
- Have congenital heart disease, valvular heart disease, and other identified cause of pulmonary hypertension (including pulmonary fibrosis) unrelated to SCD
- Have an elevated PCWP, as evidenced by E/Em > 15 by pulsed wave and tissue Doppler imaging
- Have no measurable tricuspid regurgitant velocity on echocardiography
- Have a history of major gastrointestinal bleeding or a bleeding diathesis
- Have sickle cell complications such as recent vaso-occlusive crisis or acute chest syndrome, 4-weeks prior to commencing the study
- Have a history of clinically overt stroke(s) or seizures
- Have a brain MRI/MRA scan with evidence of Moya Moya within the preceding year
- Are pregnant or breastfeeding
- Are on chronic anticoagulant therapy
- Have a history of metastatic cancer
- Are chronically on therapy with aspirin or non-steroidal anti-inflammatory agents
- Are on a chronic transfusion program or have received a blood transfusion in the prior 8 weeks
- Have a positive urine toxicology screen for cocaine and amphetamines
- Have a history of alcohol abuse
- Are currently receiving treatment with epoprostenol (or similar prostacyclin analog), sildenafil (or similar phosphodiesterase 5 inhibitor), bosentan or arginine
- Have ingested any investigational drugs within the past 4 weeks.
Contacts and Locations| Contact: Kenneth I Ataga, MD | 919-966-0178 | kataga@med.unc.edu |
| Contact: Susan Jones, RN | 919-966-6876 | skjones@med.unc.edu |
| United States, North Carolina | |
| University of North Carolina | Recruiting |
| Chapel Hill, North Carolina, United States, 27599 | |
| Contact: Kenneth I Ataga, MD 919-966-0178 kataga@med.unc.edu | |
| Contact: Susan Jones, RN 919-966-6876 skjones@med.unc.edu | |
| Sub-Investigator: Nigel S Key, MD | |
| Sub-Investigator: Alan Hinderliter, MD | |
| Sub-Investigator: Mary B Shilliday, PharmD | |
| Principal Investigator: | Kenneth I Ataga, MD | University of North Carolina, Chapel Hill |
More Information
No publications provided
| Responsible Party: | University of North Carolina, Chapel Hill |
| ClinicalTrials.gov Identifier: | NCT01036802 History of Changes |
| Other Study ID Numbers: | 09-1596, R01HL094592-01A1 |
| Study First Received: | December 18, 2009 |
| Last Updated: | July 3, 2012 |
| Health Authority: | United States: Federal Government United States: Food and Drug Administration United States: Institutional Review Board |
Keywords provided by University of North Carolina, Chapel Hill:
|
sickle cell disease pulmonary hypertension coagulation activation platelet activation endothelial activation |
Additional relevant MeSH terms:
|
Anemia, Sickle Cell Hypertension Hypertension, Pulmonary Anemia, Hemolytic, Congenital Anemia, Hemolytic Anemia Hematologic Diseases Hemoglobinopathies Genetic Diseases, Inborn |
Vascular Diseases Cardiovascular Diseases Lung Diseases Respiratory Tract Diseases Warfarin Anticoagulants Hematologic Agents Therapeutic Uses Pharmacologic Actions |
ClinicalTrials.gov processed this record on May 21, 2013